The earliest reports of aberrant activation of NRF2 through somatic mutations in KEAP1 [55] and NRF2 [56,57] were based on human non-small-cell lung carcinoma (NSCLC). The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.